--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-26-053102" form_type: "8-K" ticker: "TELA" cik: "0001561921" company_name: "TELA Bio, Inc." filed_at: "2026-04-30T23:59:59+00:00" generated_at: "2026-05-15T00:47:58.832545+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.8 calibrated_materiality_score: 0.8 confidence: "high" source: SEC EDGAR --- # TELA Bio reports preliminary Q1 revenue of $19.0M; Chairman and three directors to resign, new directors appointed ## Summary - Preliminary Q1 2026 revenue approximately $19.0M; unaudited and subject to change after close. - Chairman Doug Evans and directors Kurt Azarbarzin, Vince Burgess, Federica O'Brien to resign after 2026 annual meeting. - Board nominates Joseph Capper (CEO of MiMedx) for election as Class I director and future Chairman. - Board appoints Guido Neels, Guy Nohra, Paul Thomas as new directors effective after 2026 annual meeting. - Incoming directors and Capper to receive initial equity awards: options for 17,550 shares and RSUs for 11,925 shares. ## SEC filing metadata - accession: 0001104659-26-053102 - form_type: 8-K - ticker: TELA - cik: 0001561921 - company_name: TELA Bio, Inc. - filed_at: 2026-04-30T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.8 - calibrated_materiality_score: 0.8 - confidence: high - sec_items: 2.02, 5.02 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/tm2612982d1_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-26-053102 - JSON: https://secwatch.observer/filing/0001104659-26-053102.json - Plain text: https://secwatch.observer/filing/0001104659-26-053102.txt ## Key facts - Earnings Releases TELA Bio, Inc. reported quarter ended March 31, 2026 results: revenue approximately $19.0 million. - Period: quarter ended March 31, 2026 - Revenue: approximately $19.0 million - Result: preliminary results source text: On April 29, 2026, TELA Bio, Inc. (the " Company ") issued a press release announcing its preliminary unaudited revenue for the quarter ended March 31, 2026 of approximately $19.0 million. evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm - Executive change Kurt Azarbarzin resigned as Director at TELA Bio, Inc.. - Action: resigned - Role: Director source text: In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board... evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm - Executive change Vince Burgess resigned as Director at TELA Bio, Inc.. - Action: resigned - Role: Director source text: In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board... evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm - Executive change Guy Nohra was appointed as Director at TELA Bio, Inc.. - Action: appointed - Role: Director source text: On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors... evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm - Executive change Federica O'Brien resigned as Director at TELA Bio, Inc.. - Action: resigned - Role: Director source text: In addition, on April 29, 2026, Kurt Azarbarzin, Vince Burgess and Federica O’Brien (the “ Resigning Directors ”) each tendered his or her resignation from the Board... evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm - Executive change Paul Thomas was appointed as Director at TELA Bio, Inc.. - Action: appointed - Role: Director source text: On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director, with a term expiring at the 2027 Annual Meeting of the Company, and Guy Nohra and Paul Thomas as Class III directors... evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm - Executive change Guido Neels was appointed as Director at TELA Bio, Inc.. - Action: appointed - Role: Director source text: On April 29, 2026, in connection with the Resigning Directors’ resignations, the Board appointed Guido Neels as a Class II director... evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm - Executive change Doug Evans resigned as Chairman of the Board at TELA Bio, Inc.. - Action: resigned - Role: Chairman of the Board source text: On April 29, 2026, Doug Evans, Chairman of the Board of Directors (the “ Board ”) of the Company, notified the Company and the Board that he will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “ 2026 Annual Meeting ”) and will retire from the Board... evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465926053102/0001104659-26-053102-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.